Biotech CEO Reveals US Losing Clinical Trial Race to China Due to FDA Bottleneck

What was said

"The United States is actually in the process of very rapidly as a country falling behind China because what started as a place for American companies to come run clinical trials to get data and then take it to the FDA and then do larger trials in the United States has now created a flywheel structure within China where now just Chinese companies run their clinical trials faster than the American companies and then bring their Chinese-discovered drugs to the United States."

Jake Becraft, CEO of Strand Therapeutics, warned that China has built an industrialized clinical trial infrastructure so efficient that US companies are losing their competitive advantage. He explained that American biotech is being dragged overseas by burdensome FDA regulations, creating a capital flow to Chinese companies that can develop drugs faster and cheaper. This national security concern reached the White House, with the president including FDA reform in his legislative priorities just two months after Becraft's Washington Post op-ed.